MRG 106

Drug Profile

MRG 106

Alternative Names: MRG-106

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator miRagen Therapeutics
  • Class Antifungals; Antineoplastics
  • Mechanism of Action MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Mycosis fungoides
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adult T-cell leukaemia-lymphoma; Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 08 Nov 2017 Phase-I clinical trials in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater), Diffuse large B cell lymphoma (Monotherapy, Second-line therapy or greater) and Adult T-cell leukaemia-lymphoma (Monotherapy, Second-line therapy or greater)in USA (SC) (IV) (NCT02580552)
  • 13 Oct 2017 New interim safety and efficacy data from a phase I trial in Cutaneous T-cell lymphoma released by miRagen Therapeutics
  • 13 Oct 2017 miRagen Therapeutics plans a phase I trial for T-cell leukaemia/lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top